

Challenge and Promise in Cell and Vaccine Therapy in Asia

Plenary Speakers

Hiroshi Shiku (Mie University)

Mitsuru Miyata (Nikkei Business Publications, Inc.)

Speakers

Japan

Tsuyoshi Ando (Pharmaceuticals and Medical Devices Agency)

Yoko Funakoshi (SBI Biotech Co., Ltd.)

Satoshi Hamada (Mitsui & Co., Ltd.)

Miki Isogai (PharmaBio Co.)

Yoshiji Kimura (MEDINET Co., Ltd.)

Naoto Matsuda (Toyo Seikan Kaisha, Ltd.)

Fumitaka Nagamura (The University of Tokyo)

Hidenori Nakajima (Astellas Pharma Inc.)

Yosuke Ozawa (Japan Tissue Engineering Co., Ltd.)

Tomoki Todo (The University of Tokyo)

Korea

Jay Lee (Medipost Co., Ltd.)

China

Di Xu (Sino-American iCell (Shanghai) Biotechnology Co., Ltd.)

Malaysia

Ishak Mat (Advanced Medical & Dental Institute, Universiti Sains Malaysia)

Australia

Dominic Wall (Cell Therapies Pty Ltd.)

Taiwan

Ching-Yu Lu (Center for Drug Evaluation)

Organising Committee

Hiroshi Kiyono (The University of Tokyo)

Ken-ichi Arai (The University of Tokyo)

Sumiko Watanabe (The University of Tokyo)

Supported by

- Special Coordination Funds for Promoting Science & Technology, MEXT
Establishment of a life science research network in Asia
(Principal Investigator; Hiroshi Kiyono)
- Genomic Drug Discovery Forum

Co-sponsored by

- NPG Nature Asia-Pacific
- The Japan Institute of International Affairs
- Tomy Digital Biology Co., Ltd.

Toward Clinical Approval for Commercialization

October 16 (Tue), 2012 9:00–18:15

The Institute of Medical Science, The University of Tokyo,
Auditorium (Main building 1F)
(<http://www.ims.u-tokyo.ac.jp/imsut/en/>)

LSNAsia
Life Science Network Asia



細胞治療・ワクチン療法への挑戦

—アジア連携による製品化をめざして—

Challenge and Promise in Cell and Vaccine Therapy in Asia
-Toward Clinical Approval for Commercialization-

2012 October 16 (Tue) 9:00~18:15

Venue: Institute of Medical Science, University of Tokyo,
Auditorium (Main building 1F)

URL: <http://www.ims.u-tokyo.ac.jp/imsut/en/>

Opening		
09:00-09:10	Sumiko Watanabe (IMSUT)	
Introduction		Chair : Yoichi Furukawa
09:10-09:40	Hiroshi Shiku (University of Mie)	<i>Cancer Immunotherapy; Integration of T cell Biology with Nanogel- and Vector-Technology in Translational Research</i>
Session 1		The experiences of companies already started cell therapy Chair : Tadashi Matsumoto
09:40-10:10	Yosuke Ozawa (J-TEC)	<i>KFS and Issues in Commercializing Regenerative Medicine in Japan</i>
10:10-10:40	Jay Lee (Medipost, Korea)	<i>World's First off-the-shelf allogeneic cord-blood stem cell drug CARTISTEM® - Journey to the market from the scratch.</i>
Special Lecture		Oncolytic Virus and Cell Therapy for Cancer Chair : Masaaki Muramatsu
10:40-11:05	Tomoki Todo (IMSUT)	<i>Clinical Development of Oncolytic Virus Therapy</i>
11:05-11:20	Break	
Session 1		The experiences of companies already started cell therapy Chair : Tadashi Matsumoto
11:20-11:40	Kunihiko Suzuki (Medinet Co.,Ltd.)	<i>Alternative Path in Practice of Cell Therapy with using Immuno-Cells</i>
Special Lecture		Chair : Ken-ichi Arai
11:40-12:30	Mitsuru Miyata (Nikkei BP Inc.)	<i>Social and Legal Issues on Regenerative Medicine and Vaccine</i>
12:30-13:30	Lunch	
Session 2		Foreign and Domestic companies/organizations trying to develop cell therapy Chair : Ken-ichi Arai
13:30-13:50	Di Xu (iCell, China)	<i>The clinical research of DCCIK immunotherapy technology in advanced cancer patients</i>
13:50-14:10	Yoko Funakoshi (SBI Biotech Co.,Ltd.)	<i>SBI Biotech's strategy for the Business development of Dendritic Cell Therapy</i>
14:10-14:40	Ishak Mat (AMDI, Malaysia)	
14:40-15:00	Hidenori Nakajima (Astellas Pharma Inc.)	
15:00-15:20	Satoshi Hamada (Mitsui & Co.,Ltd.)	<i>Mitsui's healthcare investment strategy</i>
15:20-15:30	Break	

Session 3 Supporting activities providing equipments and/or facilities for approval of cell therapy		
Chair : Robert Whitter		
15:30-15:50	Naoto Matsuda (Toyo Seikan Kaisha,	<i>Development of a GMP-compliant Automated Cell Culture System Using a Closed System Bag Kit</i>
15:50-16:20	Dominic Wall (Cell Therapy Australia)	<i>Bringing cell therapy from the lab to the world</i>
16:20-16:40	Miki Isogai (Pharmabio, Japan)	<i>Products and services to support development of cell based medicine in Japan</i>
Session 4 Regulatory Considerations and Collaboration		
Chair : Sumiko Watanabe		
16:40-17:00	Fumitaka Nagamura (IMSUT)	<i>Approaches of Regulatory Agencies in US/EU for the promotion of Cell Therapies</i>
17:00-17:20	Tsuyoshi Ando (PMDA)	<i>PMDA's Efforts in Medical Innovation - Regenerative Medicine-</i>
17:20-17:50	Ching-Yu Lu (CDE, Taiwan)	<i>The Regulation and Development of Cell Therapy Products in Taiwan</i>
17:50-18:00	Matthew Salter (NPG Nature Asia-Pacific)	
Concluding remarks		
18:00-18:15	Ken-ichi Arai (The University of Tokyo)	
18:30-20:30	Reception	(8F Tomy Hall, Hospital Building)